Kymera and Gilead sign option/license deal for CDK2 degraders; up to $750M

Kymera Therapeutics, Inc.

Up to $750M total payments including $85M upfront/option exercise payments.
Tiered royalties ranging from high-single-digit to mid-teens on net sales.
Kymera leads all research; Gilead obtains global development/manufacturing/commercialization rights.
CDK2 degraders target breast cancer and other solid tumors.
Agreement announced June 25, 2025.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.